Zadaxin fails second HCV Phase III

SciClone (SCLN) said Zadaxin plus pegylated interferon (IFN) alpha missed the primary endpoint of sustained virologic response (SVR) rate vs. IFN alpha and placebo in a Phase III trial to treat HCV infection in 500 patients with early cirrhosis of the liver who have failed prior therapy. In December, Zadaxin missed the co-primary endpoints of SVR and histological improvement in another Phase III trial for HCV (see BioCentury Extra, Wednesday Dec. 14, 2005). ...